IN2014MN00697A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MN00697A IN2014MN00697A IN697MUN2014A IN2014MN00697A IN 2014MN00697 A IN2014MN00697 A IN 2014MN00697A IN 697MUN2014 A IN697MUN2014 A IN 697MUN2014A IN 2014MN00697 A IN2014MN00697 A IN 2014MN00697A
- Authority
- IN
- India
- Prior art keywords
- receptor
- refers
- prophylaxis
- selectivity
- medicament
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
The present invention belongs to the field of EP1 receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EP1 receptor. The invention also refers to the process for their preparation to their use as medicament for the treatment and/or prophylaxis of diseases or disorders mediated by the EP1 receptor as well as to pharmaceutical compositions comprising them.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11382296A EP2570125A1 (en) | 2011-09-16 | 2011-09-16 | Ep1 receptor ligands |
PCT/EP2012/068101 WO2013037960A1 (en) | 2011-09-16 | 2012-09-14 | Ep1 receptor ligands |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014MN00697A true IN2014MN00697A (en) | 2015-07-03 |
Family
ID=46851508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN697MUN2014 IN2014MN00697A (en) | 2011-09-16 | 2012-09-14 |
Country Status (19)
Country | Link |
---|---|
US (1) | US9518015B2 (en) |
EP (2) | EP2570125A1 (en) |
JP (1) | JP6041880B2 (en) |
KR (1) | KR20140061475A (en) |
CN (1) | CN104220422B (en) |
AR (1) | AR092288A1 (en) |
AU (1) | AU2012307326A1 (en) |
BR (1) | BR112014006305A2 (en) |
CA (1) | CA2848786A1 (en) |
CO (1) | CO6970588A2 (en) |
ES (1) | ES2629481T3 (en) |
HK (1) | HK1201269A1 (en) |
IL (1) | IL231518A0 (en) |
IN (1) | IN2014MN00697A (en) |
MA (1) | MA35444B1 (en) |
MX (1) | MX346143B (en) |
SG (1) | SG11201400680RA (en) |
TN (1) | TN2014000112A1 (en) |
WO (1) | WO2013037960A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2702237T3 (en) * | 2011-12-21 | 2019-02-28 | Allergan Inc | Compounds that act on multiple prostaglandin receptors that give a general anti-inflammatory response |
CN106232603B (en) | 2014-05-01 | 2019-07-05 | 诺华股份有限公司 | Compound and composition as 7 agonist of TOLL- sample receptor |
ES2908150T3 (en) | 2014-05-01 | 2022-04-27 | Novartis Ag | Compounds and Compositions as Toll-like Receptor 7 Agonists |
BR112016026193B1 (en) | 2014-05-23 | 2021-06-22 | Fmc Corporation | COMPOUND, METHOD FOR PREPARING A COMPOUND OF FORMULA I AND METHOD FOR PREPARING A COMPOUND OF FORMULA IV |
CN103992319B (en) * | 2014-05-27 | 2015-09-16 | 天津市斯芬克司药物研发有限公司 | A kind of preparation method of pyridine carboxylic acid compounds |
WO2016014918A1 (en) * | 2014-07-25 | 2016-01-28 | Innov 17 Llc | Benzimidazole retinoic acid receptor-related orphan receptor modulators and uses thereof |
CA2989270A1 (en) * | 2015-06-16 | 2016-12-22 | Translatum Medicus, Inc. | Compositions and methods for treating and diagnosing ocular disorders |
MA44334A (en) | 2015-10-29 | 2018-09-05 | Novartis Ag | ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST |
US11518739B2 (en) | 2017-08-15 | 2022-12-06 | Inflazome Limited | Sulfonamide carboxamide compounds |
CA3144861A1 (en) | 2019-06-25 | 2020-12-30 | Translatum Medicus, Inc. | Processes of making 2-((1-benzyl-1h-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives |
EP4225742A1 (en) | 2020-10-05 | 2023-08-16 | Enliven Therapeutics, Inc. | 5- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinases |
CN114163438A (en) * | 2021-12-13 | 2022-03-11 | 无锡捷化医药科技有限公司 | Preparation method of 2-methyl-3-carbonyl pyrazolo [4,3-c ] pyridine-7-carboxylic acid hydrochloride |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6348032B1 (en) * | 1998-11-23 | 2002-02-19 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with benzimidazole derivatives |
US7153852B2 (en) * | 2001-09-07 | 2006-12-26 | Ono Pharmaceutical Co., Ltd. | Indole compounds, process for producing the same and drugs containing the same as the active ingredient |
GB0212785D0 (en) * | 2002-05-31 | 2002-07-10 | Glaxo Group Ltd | Compounds |
GB0225548D0 (en) * | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Compounds |
GB0306329D0 (en) * | 2003-03-19 | 2003-04-23 | Glaxo Group Ltd | Compounds |
AU2003902860A0 (en) * | 2003-06-06 | 2003-06-26 | Daicel Chemical Industries, Ltd | Benzimidazole compounds |
US20070060596A1 (en) * | 2003-10-24 | 2007-03-15 | Giblin Gerard M P | Heterocyclyl compounds |
GB0428263D0 (en) * | 2004-12-23 | 2005-01-26 | Glaxo Group Ltd | Compounds |
AR052429A1 (en) * | 2004-12-23 | 2007-03-21 | Glaxo Group Ltd | ARILPIRIDINE COMPOSITE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, ITS USE FOR THE PREPARATION OF A MEDICINAL PRODUCT AND PROCEDURE TO PREPARE IT |
AU2009272033B2 (en) * | 2008-07-17 | 2011-10-13 | Asahi Kasei Pharma Corporation | Nitrogenated heterocyclic compound |
EP2566328B1 (en) | 2010-05-07 | 2015-03-04 | GlaxoSmithKline LLC | Indazoles |
-
2011
- 2011-09-16 EP EP11382296A patent/EP2570125A1/en not_active Withdrawn
-
2012
- 2012-09-14 BR BR112014006305A patent/BR112014006305A2/en not_active Application Discontinuation
- 2012-09-14 AU AU2012307326A patent/AU2012307326A1/en not_active Abandoned
- 2012-09-14 CA CA2848786A patent/CA2848786A1/en not_active Abandoned
- 2012-09-14 ES ES12759142.8T patent/ES2629481T3/en active Active
- 2012-09-14 WO PCT/EP2012/068101 patent/WO2013037960A1/en active Application Filing
- 2012-09-14 JP JP2014530243A patent/JP6041880B2/en not_active Expired - Fee Related
- 2012-09-14 IN IN697MUN2014 patent/IN2014MN00697A/en unknown
- 2012-09-14 EP EP12759142.8A patent/EP2766344B1/en not_active Not-in-force
- 2012-09-14 KR KR1020147008452A patent/KR20140061475A/en not_active Application Discontinuation
- 2012-09-14 US US14/345,136 patent/US9518015B2/en active Active
- 2012-09-14 CN CN201280056411.1A patent/CN104220422B/en not_active Expired - Fee Related
- 2012-09-14 SG SG11201400680RA patent/SG11201400680RA/en unknown
- 2012-09-14 MX MX2014003169A patent/MX346143B/en active IP Right Grant
- 2012-09-17 AR ARP120103434A patent/AR092288A1/en unknown
-
2014
- 2014-03-13 IL IL231518A patent/IL231518A0/en unknown
- 2014-03-14 MA MA36834A patent/MA35444B1/en unknown
- 2014-03-14 TN TNP2014000112A patent/TN2014000112A1/en unknown
- 2014-03-17 CO CO14056611A patent/CO6970588A2/en not_active Application Discontinuation
-
2015
- 2015-02-20 HK HK15101826.1A patent/HK1201269A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU2012307326A1 (en) | 2014-03-27 |
TN2014000112A1 (en) | 2015-07-01 |
BR112014006305A2 (en) | 2017-04-11 |
CA2848786A1 (en) | 2013-03-21 |
US20140323475A1 (en) | 2014-10-30 |
KR20140061475A (en) | 2014-05-21 |
JP6041880B2 (en) | 2016-12-14 |
CN104220422A (en) | 2014-12-17 |
JP2014530184A (en) | 2014-11-17 |
MA35444B1 (en) | 2014-09-01 |
EP2766344B1 (en) | 2017-05-03 |
IL231518A0 (en) | 2014-04-30 |
ES2629481T3 (en) | 2017-08-10 |
AR092288A1 (en) | 2015-04-15 |
EP2766344A1 (en) | 2014-08-20 |
EP2570125A1 (en) | 2013-03-20 |
WO2013037960A1 (en) | 2013-03-21 |
SG11201400680RA (en) | 2014-06-27 |
MX2014003169A (en) | 2014-04-25 |
HK1201269A1 (en) | 2015-08-28 |
CN104220422B (en) | 2017-11-07 |
CO6970588A2 (en) | 2014-06-13 |
US9518015B2 (en) | 2016-12-13 |
MX346143B (en) | 2017-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014MN00697A (en) | ||
IN2014MN00988A (en) | ||
MD4496C1 (en) | 2'-Substituted carba-nucleoside analogs for antiviral treatment | |
EA024842B9 (en) | Compounds as modulators of pi3k protein kinase | |
MD20150091A2 (en) | Anti-viral compounds | |
PH12014502524B1 (en) | Carboxylic acid compounds | |
IN2014CN04907A (en) | ||
MX349004B (en) | New compounds. | |
EA201391561A1 (en) | NEW CONNECTIONS-MODULATORS GPR-119 | |
IN2014MN00986A (en) | ||
PH12014501514A1 (en) | New azetidine derivatives, pharmaceutical compositions and uses thereof | |
GB201118656D0 (en) | New compounds | |
GB2511685A (en) | Muscarinic m1 receptor agonists | |
EA201500298A1 (en) | ALCOXYPHAZOLES AS ACTIVATORS OF SOLUBLE GUANYLATZYCLASES | |
WO2013061004A8 (en) | Novel disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases | |
PH12014501195A1 (en) | Novel 2h-indazoles as ep2, receptor antagonists | |
MX2014004858A (en) | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated pathologies. | |
MX2014000964A (en) | Substituted heterocyclic aza derivatives. | |
WO2012104823A3 (en) | Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases | |
PH12014501943A1 (en) | Novel compounds for the treatment of dyslipidemia and related diseases | |
IN2013DN02555A (en) | ||
MX2014000963A (en) | Substituted bicyclic aromatic carboxamide and urea derivatives as vanilloid receptor ligands. | |
UA117780C2 (en) | Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators | |
MX2014003584A (en) | Substituted methanesulfonamide derivatives as vanilloid receptor ligands. | |
MX2014003455A (en) | Aryl or n-heteroaryl substituted methanesulfonamide derivatives as vanilloid receptor ligands. |